ABOUT US
Vision Statement
Neopharma Technologies aims to be the recognized global leader for innovative Drugs of Abuse healthcare technologies. To promote a healthier and safer world.
Vision Statement
Mission Statement
To have NEOVAULT become the world's default digital testing platform.
Neopharma Technologies Ltd is an Australian public company that aims to be a global leader the multi-billion-dollar global Point-of-Care Health testing market with its NEOVAULT AI paperless testing solution and its range of Rapid Test kits.
Leadership Team
MARCUS L’ESTRANGE
Marcus is an Engineer who has extensive experience in the IT Industry, the Mining Industry, the Oil and Gas Industry, and the Environmental Industry. He has been involved with the start-up of several successful companies within these sectors. He has a diverse range of skills as an engineer as well as in sales and marketing and business development. Marcus is the Managing Director of Raptor Global Corporation Ltd, an Australian public company with an Australian Financial Services License (AFSL) that provides corporate services to assist companies to grow globally. Marcus was also previously the Chairman of Cirralto, an ASX listed IT company.
SHAUN MELVILLE
Shaun Melville has a wide range of experience in Sales and Marketing across industries of IT, Health, Mining, and Financial Services. Shaun has a Bachelor’s degree in Psychology. Shaun recently completed his Oxford Executive Leadership Course with a final overall result of 93.7%. Shaun is currently an Executive Director of Raptor Global Corporation Ltd, an Australian public company with an Australian Financial Services License (AFSL) that provides corporate services to assist companies to grow globally.
GAJENDDRA RAJ
Gajenddra is an entrepreneurial-spirited, pioneering technologist with executive-level experience identifying, qualifying, building, implementing, and enabling technologies and enterprise systems that facilitate business processes and strategic objectives. Skilled in all phases of the software development lifecycle; expert in translating business requirements into technical solutions; with a focus on quality, usability, security, and scalability. Broad expertise in IT, infrastructure, and security with architecture/ infrastructure design, full project life cycle management, and operational management.
Gajenddra has been the Chief Technology Officer for Neopharma Technologies Ltd since the inception of the company in June 2017. He has driven and managed the development of DataVault and is the principal technical liaison officer with NTL’s international clients.
NINA M FRENCH
Nina M. French has more than 30 years of experience in the employee screening industry and a deep understanding of drug testing program design, policies, state laws, federal regulations, product development and supporting technologies. In addition to executive leadership roles both at one of the largest Third-Party Administrators in the industry and at two product innovation firms, Nina has served as the President of DATIA and as an industry advisor to TPAs and CRAs across the country at her prior consulting firm.
Nina frequently speaks at conferences and regularly contributes to the thought leadership of the drug and alcohol testing industry. She is widely published and is featured on podcasts, interviews and publications in safety, drug testing, and human resources.
JOSEPH DAVIES
Joseph is a dynamic and results-oriented executive with a strong foundation in natural health, management and dental distribution. He has demonstrated success in driving significant revenue growth, fostering strategic partnerships, and spearheading international market expansion. Expert in developing robust supply chains and building new business territories from the ground up.
Joseph was General Manager and subsequently CEO and Executive Chairman of TRI Dental ANZ Ltd over 8 years, he led the introduction of the cutting-edge TRI-matrix implant range into Australia and New Zealand, reshaping market dynamics and positioning the brand as an industry innovator. Adept at crafting high-impact strategies, executing market innovation initiatives, and managing large-scale events, he thrives in challenging environments where growth, collaboration, and strategic vision are key to success.
INDUSTRY STANDARDS
International Data Security Certifications
At Neopharma Technologies, we pride ourselves on maintaining the highest standards of data security, privacy, and compliance. Our adherence to multiple international certifications and standards aligns with our commitment to protecting our clients' sensitive information and maintaining their trust, adhering to the highest international standards of data security, privacy, and regulatory compliance.
The ISO 27001 certification. This internationally recognized standard validates our comprehensive Information Security Management System (ISMS). It assures our clients that we have implemented robust processes to identify, assess, and mitigate risks related to information security. Our ISO 27001 certification is a testament to our proactive approach in safeguarding data confidentiality, integrity, and availability across our operations.
SOC2 Type 2 compliance reflects Neopharma's commitment to maintaining rigorous controls over an extended period. This certification, developed by the American Institute of CPAs, focuses on our systems' security, availability, processing integrity, confidentiality, and privacy. With our digitised workflow being SOC 2 Type 2 compliant, our clients can be confident that our internal controls and processes have been thoroughly audited and proven effective in protecting their data and delivering high-quality services consistently.
GDPR certification showcases Neopharma's global commitment to data protection and privacy. These comprehensive EU regulations require robust measures to protect personal data and respect individual privacy rights. Our GDPR compliance demonstrates our readiness to operate on a global scale while adhering to some of the world's most stringent privacy requirements.
HIPAA compliance to stringent U.S. regulatory standards for protecting sensitive patient health information. Our HIPAA compliance signifies that we have implemented comprehensive safeguards to ensure the confidentiality and security of all protected health information (PHI) we handle. It reassures our healthcare clients and partners that we meet the strict requirements for data protection in the healthcare sector.
Professional Industry Body Memberships and Associations
Neopharma Technologies proudly sponsors and supports top industry associations globally. Our aim is to provide valuable resources, attend key events, and showcase our distinctive range of products and services to the market.
NDASA is the voice of the nation’s drug and alcohol screening industry. Our diverse membership includes testing companies, employers, laboratories, Third Party Administrators, human resources managers, safety professionals, substance abuse counselors and others. We stand together to maintain drug-free workplaces and protect public safety.
To promote our industry’s interests, NDASA provides best-practices professional training and certification, hosts national and regional educational conferences, offers informational resources, leads governmental advocacy efforts on federal and state levels, and works closely with regulators who impact our industry, including the U.S. Department of Transportation.
At SAPAA, we position ourselves as your workforce partner in progress, dedicated to excellence in the workforce drug and alcohol testing industry. SAPAA serves as the professional nucleus for a diverse range of members, including Alcohol and Drug Testing Service Agents & Suppliers, Third-Party Administrators, Direct Employers, Medical Review Officers, DHHS Certified Laboratories, Substance Abuse Professionals/Experts, Manufacturers of Testing Devices, and Collection Sites/Collectors.
Australia’s Peak Industry Body for the Workplace Drug Testing Industry.
The Workplace Drug Testing Association (WDTA) is the Peak National Body representing the broad interests of the workplace drug testing sector in Australasia.
WDTA represent the interests of our Membership to help establish and uphold quality frameworks that support professional drug testing service delivery. We do this through participation on various Standards Committees and developing our own supporting guidelines designed to fill operational gaps and address technical issues in existing Standards.
We also provide information to organizations who are considering introducing a drug and alcohol program about key issues to consider and effective solutions that can be considered.
The tech behind the test. Pathology technology drives the provision of high quality, accessible and affordable healthcare services. We represent the manufacturers and importers of technologies that enables pathology testing in laboratories, hospitals and the community.
Pathology Technology Australia Ltd is the peak industry body representing manufacturers and importers of tests and technologies, vital to testing patient samples in the pathology laboratory, in hospitals and in the primary care setting. This technology enables more than 800 million tests to be perform in Australia every year.
Our members not only develop, manufacture and supply this technology, they also train doctors and scientists in its use, provide technical specialists to service it, constantly monitor and improve quality and maintain the supply chain. In effect, we make pathology possible.
What makes us an Industry Leader
INTEGRITY
We do what’s right
LEADERSHIP
We serve others
We are modest and respectful
ACCOUNTABILITY
We do what we say
HUMILITY
We seek continuous improvement
PEOPLE
We grow talent
INNOVATION
PERFORMANCE
We deliver